Genedrive
GDR · AIM · Health Care · mcap £18m · 1.1p
| Date | Type | Announcement | Day |
|---|---|---|---|
| 10 Sep 26 | Welsh hospitals extend routine MT-RNR1 testing
Welsh hospitals extend routine clinical service of genedrive's MT-RNR1 test |
−1.9% | |
| 03 Sep 26 | ShareSoc Investor Presentation Reminder
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is conducting a ShareSoc webinar at 11:00am (BST) today. |
+0.0% | |
| 01 Sep 26 | Director dealing | Director/PDMR Shareholding
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company announces that on 28 August 2026, Dr Gino Miele, Chief Executive Officer, acquired 700,000 Ordinary Shares in the Company at a price of 1.38p pe |
+0.0% |
| 21 Aug 26 | Board Appointments
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr Mark Winkler and Mr Mike Fairbourn have agreed to join the Board as independent Non-Executive Directors with effect fro |
−3.7% | |
| 13 Aug 26 | ShareSoc Investor Presentation
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that it will be presenting a live ShareSoc webinar on Thursday 3 September 2026 at 11:00am (BST). |
+0.0% | |
| 11 Aug 26 | Completion of PALOH-UK Patient Recruitment
Completion of PALOH-UK Patient Recruitment for Genedrive® MT-RNR1 ID Kit |
+4.3% | |
| 04 Aug 26 | MT-RNR1 test implemented in the Netherlands
Genedrive® MT-RNR1 ID Kit implemented at Erasmus MC University Medical Center in the Netherlands |
+15.0% | |
| 03 Aug 26 | New UK clinical guideline for MT-RNR1 testing
New UK clinical guideline published for MT-RNR1 genotype testing |
+0.0% | |
| 14 Jul 26 | Board change | Board Appointment
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr. |
−4.3% |
| 13 Jul 26 | Trading update | Trading Update
- Strong commercial progress and poised for continued growth in the next 12 months |
−7.8% |
| 10 Jul 26 | UK Minister highlights pharmacogenetic testing
UK Health Minister highlights NIHR Manchester Biomedical Research Centre's adoption of rapid pharmacogenetic testing for antibiotic-induced hearing loss during Parliamentary Committee |
+4.1% | |
| 01 Jul 26 | Board change | Directorate Change
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that further to the Company's announcement of 26 May 2026 detailing various immediate and proposed board changes, Dr. |
+0.0% |
| 29 Jun 26 | CYP2C19 Agreement with Thermo Fisher Scientific
CYP2C19 Product Development Collaboration agreement with Thermo Fisher Scientific Inc. |
+0.0% | |
| 18 Jun 26 | Manchester NHS Trust transitions MT-RNR1 to BAU
Manchester University NHS Foundation Trust transitions genedrive's MT-RNR1 test to Business as Usual clinical service |
+6.1% | |
| 05 Jun 26 | Receipt of R&D tax credit
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, confirms it has received an R&D tax credit refund of approximately £0.76m from HMRC in respect of the financial years ended 30 June 2024 and 30 |
+6.0% | |
| 26 May 26 | Board change | Directorate Change
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that Mr David Nugent has joined the Board as a Non-Executive Director with immediate effect. |
+4.3% |
| 05 May 26 | Sussex NHS Trust transitions MT-RNR1 test to BAU
University Hospitals Sussex NHS Foundation Trust transitions genedrive's MT-RNR1 test to Business as Usual clinical service |
+0.0% | |
| 21 Apr 26 | NHS England commercial strategy for MT-RNR1
Consultation to inform NHS England commercial strategy for rapid MT-RNR1 testing |
−5.0% | |
| 20 Apr 26 | Interactive Investor Hub Updates
genedrive Updates Interactive Investor Hub to Support Shareholder Engagement |
+5.3% | |
| 16 Apr 26 | CYP2C19 kit implemented in North Bristol NHS Trust
Implementation of Genedrive® CYP2C19 ID Kit in North Bristol NHS Trust Southmead Hospital |
+0.0% | |
| 30 Mar 26 | Results | Half-year Results
- Capitalised to expand commercial operations in the UK and internationally |
−2.6% |
| 09 Mar 26 | Fundraise | Result of Open Offer and Additional Subscriptions
Manchester, UK - 9 March 2026: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces that that it has conditionally raised total gross proceeds of approximately £0.91 million through the |
−7.0% |
| 13 Feb 26 | Fundraise | Completion of Placing
Manchester, UK - 13 February 2026: genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, announces the completion of the placing (the "Placing") which was announced earlier today. |
+11.6% |
| 13 Feb 26 | Fundraise | Proposed Direct Subscription to raise up to £3.5m
Proposed Direct Subscription to raise up to £3.5 million, Placing to raise up to £0.5 million and an Open Offer to raise up to circa £1.5 million to support various growth initiatives (the "Fundraising") |
+11.6% |
| 19 Jan 26 | Proposed equity raise of up to £6.0 million
Significant indicated support from two major shareholders for an equity raise of up to £6.0 million |
+2.8% | |
| 18 Dec 25 | Scotland NHS “test of change” pilot programme
Genedrive's CYP2C19 ID kit piloted as a "test of change" in Scotland NHS Grampian and Western Isles |
+0.0% | |
| 11 Dec 25 | New interactive investor hub
genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company, is pleased to announce the launch of our interactive investor hub. |
−2.4% | |
| 09 Dec 25 | Agreement of Shareholder Loan
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 19 November 2025 confirming that heads of term had been agreed for a potential share |
+11.1% | |
| 08 Dec 25 | Results | Annual Report and Accounts and date of AGM
Annual Report and Accounts and date of AGM |
−10.0% |
| 05 Dec 25 | Results | Final Results
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, announces its audited Final Results for the year ended 30 June 2025. |
+2.6% |
| 01 Dec 25 | Results | Results presented re. NHS CYP2C19 Genotype Testing
Pilot Programme Study Results underpinning NHS Implementation Guide for CYP2C19 Genotype Testing Presented at the UK Stroke Forum |
−2.4% |
| 27 Nov 25 | NHS implementation guide published for CYP2C19
NHS implementation guide published for CYP2C19 genotype testing |
+0.0% | |
| 26 Nov 25 | Scotland national roll-out of MT-RNR1 ID Kit
Scotland national roll-out of Genedrive® MT-RNR1 ID Kit |
+5.1% | |
| 19 Nov 25 | Further re Shareholder Loan
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, is pleased to announce that further to the announcement of 31 October 2025 in relation to a potential shareholder loan (the "Loan") from David |
+9.9% | |
| 04 Nov 25 | MT-RNR1 ID Kit in Dublin’s Rotunda Hospital
Genedrive® MT-RNR1 ID Kit implemented at Dublin's Rotunda Hospital |
+5.1% | |
| 31 Oct 25 | Potential Shareholder Loan
genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, today announces an update regarding discussions with David Nugent, a 16% shareholder in the Company including via a limited company. |
+22.8% | |
| 28 Oct 25 | MOU with Kingdom of Saudi Arabia for MT-RNR1 ID
Memorandum of Understanding with Kingdom of Saudi Arabia Ministry of Health |
+37.1% | |
| 24 Oct 25 | Application for Listing & Total Voting Rights
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, confirms that warrants have been exercised that were issued in connection to the Equity Prepayment facility that was announced on 31 March 2023 |
−6.9% | |
| 09 Oct 25 | Further re Equity Financing
genedrive plc (LSE: GDR) Further to the Company's announcement on 6 October 2025 the Company has noted extensive postings on online bulletin boards which it believes to be made by David Nugent ("the Shareholder"), a 10.1 |
+44.9% | |
| 06 Oct 25 | Further re Equity Financing
genedrive plc (LSE: GDR), the point of care pharmacogenetic testing company today responds to comments and speculation on online bulletin boards that other financing options may have been available to the Company and/or |
+0.0% |
Company filings. Not investment advice.